| BioWorld

EA Pharma has presented the pharmacological characterization of the company's oral alpha4beta7 integrin antagonist AJM-347, in development as a treatment for inflammatory bowel disease (IBD). Read More

Preclinical data support clinical evaluation of iOnctura's autotaxin inhibitor IOA-289

Recursion initiates IND-enabling studies of its novel small molecule toxin inhibitor

Data reported from CRPC cohort 6 of COSMIC-021 study of cabozantinib plus atezolizumab

NextCell Pharma initiates phase I study of ProTrans in patients with COVID-19

GR antagonist CORT-125329 shows selectivity and activity in vitro and in vivo

Janssen Biotech discloses new dihydroorotate dehydrogenase inhibitors

New PARP-1 inhibitors described by Kukje Pharma, Chungnam National University

New CD38 inhibitors discovered at Mitobridge

Xilio and Merck & Co. collaborate on anti-CTLA-4 MAb program

Moleculin receives clearance to initiate phase Ib/II study of annamycin for STS lung metastases

Phase I data presented for MEDI-6570 in patients with T2DM

Sonelokimab shows significant clinical benefit over placebo in patients with plaque psoriasis

Results published from trial evaluating a therapeutic based on equine polyclonal Abs for COVID-19

Sparrow Pharmaceuticals presents new data on SPI-62 for Cushing's syndrome

Spruce Biosciences reports phase IIa data on tildacerfont in classic congenital adrenal hyperplasia

FDA places clinical hold on Larimar's CTI-1601 for Friedreich's ataxia

FDA approves IND for NBL-015 anti-Claudin 18.2 antibody

Connect begins phase I trial of CBP-174 for chronic inflammatory pruritus

Abivax reports phase IIb data on ABX-464 in moderate to severe ulcerative colitis

BioWorld Science

May 26, 2021

NCX-667 demonstrates IOP-lowering ability in a number of animal models

Targeting senescent cells restores kidney function

Boehringer Ingelheim accepts DCR-LIV2 as development candidate under Dicerna agreement

Aptorum advances ALS-4 and SACT-1 programs

Vacdiagn Biotechnology patents recombinant viral vector encoding tumor antigens

NanoCarrier describes shRNA/siRNA targeting mutant COL3A1

First data for AJM-347 shows promise for the treatment of IBD

Preclinical data support clinical evaluation of iOnctura's autotaxin inhibitor IOA-289

Recursion initiates IND-enabling studies of its novel small molecule toxin inhibitor

Data reported from CRPC cohort 6 of COSMIC-021 study of cabozantinib plus atezolizumab

NextCell Pharma initiates phase I study of ProTrans in patients with COVID-19

GR antagonist CORT-125329 shows selectivity and activity in vitro and in vivo

Janssen Biotech discloses new dihydroorotate dehydrogenase inhibitors

New PARP-1 inhibitors described by Kukje Pharma, Chungnam National University

New CD38 inhibitors discovered at Mitobridge

Xilio and Merck & Co. collaborate on anti-CTLA-4 MAb program

Moleculin receives clearance to initiate phase Ib/II study of annamycin for STS lung metastases

Phase I data presented for MEDI-6570 in patients with T2DM

Sonelokimab shows significant clinical benefit over placebo in patients with plaque psoriasis

Results published from trial evaluating a therapeutic based on equine polyclonal Abs for COVID-19

Sparrow Pharmaceuticals presents new data on SPI-62 for Cushing's syndrome

Spruce Biosciences reports phase IIa data on tildacerfont in classic congenital adrenal hyperplasia

FDA places clinical hold on Larimar's CTI-1601 for Friedreich's ataxia

FDA approves IND for NBL-015 anti-Claudin 18.2 antibody

Connect begins phase I trial of CBP-174 for chronic inflammatory pruritus

Abivax reports phase IIb data on ABX-464 in moderate to severe ulcerative colitis

Today's news in brief

News in brief

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

At AACR: Epigenetic fingerprints in metastases track tumor origin

AACR 2026: The age of agentic AI in oncology